HR19042 capsule ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
66	IgA nephropathy	2

66. IgA nephropathy

---

Clinical trials : 255 /  Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05016323 (ClinicalTrials.gov)	September 9, 2021	17/8/2021	A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	IgA Nephropathy	Drug: HR19042 Capsules;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.	NULL	Recruiting	18 Years	N/A	All	210	Phase 2	China
2	NCT04887532 (ClinicalTrials.gov)	July 1, 2021	13/5/2021	A Trial of HR19042 Capsule in Healthy Chinese Subjects	Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects	Primary IgA Nephropathy	Drug: HR19042 capsule	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	45 Years	All	12	Phase 1	China